MD&M West 2025

February 4-6, 2025

We are excited to announce Eurofins EAG Laboratories will exhibit and present at MD&M West in Anaheim February 4-6, 2025, in booth number 2899. 

Dr. Philip Ferko, Senior Scientist with EAG, will present in the MD&M West Center Stage at 12pm on February 4.

Presentation Title: Regulatory Update: Game-Changing FDA Guidance for Part 18 Studies

Abstract: Significant changes in the FDA interpretation of chemical characterization under ISO 10993-18 are occurring. In 2024 the FDA released the “Chemicals List for Analytical Performance” and draft guidance “Chemical Analysis for Biocompatibility Assessment of Medical Devices”. The FDA also held a Public Workshop discussing the “Accreditation Scheme for Conformity Assessment and Use of Chemical Analysis to Support Biocompatibility of Medical Devices”. Clearly, the FDA is defining expectations of the Chemical Characterization programs, and the analytical testing labs must adapt to continue producing effective chemical characterization reports. This talk will discuss key changes and relevant questions to ask any analytical laboratory prior to performing chemical characterization work.

View more information about Dr. Ferko’s presentation or contact us to learn more about medical device testing solutions. 

We hope to see you there!

More content you might like...

Battery Analysis after Application/Use

Battery Analysis after Application/Use

Eurofins EAG Laboratories is your partner for battery materials testing throughout the battery life cycle. From raw materials to product failures, we can provide the data needed to help you provide top quality and high-performance products to market faster.

Read More »
Solar PV industry services from EAG Laboratories

Solar/PV Testing

EAG provides solar industry with expert analysis of material properties, composition and chemistry to improve supply chain and manufacturing.

Read More »

TEM

To enable certain features and improve your experience with us, this site stores cookies on your computer. Please click Continue to provide your authorization and permanently remove this message.

To find out more, please see our privacy policy.